达布扎琼
| 中文名称 | 达布扎琼 |
|---|---|
| 中文同义词 | N-[6-氯-3-[(4,5-二氢-1H-咪唑-2-基)甲氧基]-2-甲基苯基]甲磺酰胺;达布扎琼 |
| 英文名称 | Dabuzalgron |
| 英文同义词 | MethanesulfonaMide, N-[6-chloro-3-[(4,5-dihydro-1H-iMidazol-2-yl)Methoxy]-2-Methylphenyl]-;N-[6-chloro-3-(4,5-dihydro-1H-imidazol-2-ylmethoxy)-2-methyl-phenyl]me thanesulfonamide;Dabuzalgron;Ro 115-1240;membrane,potential,inhibit,Adrenergic Receptor,mitochondrial,urinary,Inhibitor,Beta Receptor,incontinence,Cell,Dabuzalgron,death,Apoptosis |
| CAS号 | 219311-44-1 |
| 分子式 | C12H16ClN3O3S |
| 分子量 | 317.79 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 219311-44-1.mol |
| 结构式 |  |
达布扎琼 性质
| 密度 | 1.46 |
|---|---|
| 储存条件 | Store at -20°C |
| 溶解度 | 二甲基亚砜：26 mg/mL（81.82 mM） |
| 形态 | 固体 |
| 颜色 | 白色至米白色 |
α-1A adrenergic receptor
Dabuzalgron treatment increases ERK phosphorylation in a dose-dependent fashion with an
EC
50
of 4.8 μM. ERK1/2 activation contributes to the cardioprotective effects of Dabuzalgron.
Dabuzalgron (10 μM; 4 hours) protects NRVMs from cell death due to Doxorubicin (DOX).
Activation of the α1A-AR with Dabuzalgron (10 μM; 4 hours) mitigates the detrimental effects of DOX on mitochondrial membrane potential and abrogates the activation of important elements of the apoptotic response to mitochondrial damage.
Western Blot Analysis
| Cell Line: | Neonatal rat ventricular myocytes (NRVMs) |
| Concentration: | 0.1 μM, 1 μM, 10 μM and 100 μM |
| Incubation Time: | 15 minutes |
| Result: | Increased ERK phosphorylation in a dose-dependent fashion with an EC 50 of 4.8 μM. |
Dabuzalgron (10 μg/kg; oral gavage; twice daily; for 7 days; C57Bl6J wild-type or α1A-AR knockout mice) treatment protects against DOX cardiotoxicity by activating the α1A-AR. Dabuzalgron protects against the reduction in transcripts related to mitochondrial function, up-regulates PGC1α, preserves ATP content, and reduces oxidative stress in the hearts of mice treated with DOX.
| Animal Model: | Male C57Bl6J wild-type (WT) or α1A-AR knockout (AKO) mice (8-12-week-old) injected with Doxorubicin (DOX) |
| Dosage: | 10 μg/kg |
| Administration: | Oral gavage; twice daily; for 7 days |
| Result: | Preserved contractile function and reduced fibrosis after DOX administration. AKO mice treated with DOX had worse survival and more profoundly impaired contractile function than WT mice. Protected against the reduction in transcripts related to mitochondrial function, preserved ATP content, and reduced oxidative stress in the hearts of mice treated with DOX. |
安全信息
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024/08/19 | HY-117071 | Dabuzalgron | 1 mg | 352元 | |
| 2024/08/19 | HY-117071 | 达布扎琼 Dabuzalgron | 219311-44-1 | 5mg | 880元 |